Heart failure: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• SGLT2 29
• GLP-1 6
• TTR 10
• AMPK 0
• NLRP3 0
• NRF2 0
• PI3K 0
• PPAR 0
• AKT 0
• mTOR 0
• HER2 2
• STAT3 0
• TP53 0
• MAPK 0
• SIRT1 0
• STING 0
• EGFR 0
• GIP 4
• HIF-1 0
• PCSK9 0
• DPP-4 0
• VEGF 0
• HMGB1 0
• IL-6 0
• CTNNB1 0
• TNF 0
• PINK1 0
• YAP 0
• ERK 0
• GPX4 0
• JAK 0
• TLR4 0
• IL-1 0
• JNK 0
• HSP90 0
• MEK 1
• DMD 0
• IL-17 0
• MMP-9 0
• PD-1 0
• CD40 0
• COX-2 0
• HDAC 0
• PD-L1 0
• TFEB 0
• ABL1 0
• APOE 0
• AR 0
• BCL-2 0
• FTO 0
• METTL3 0
• MYC 0
• PTEN 0
• ACE2 0
• BDNF 0
• BRAF 0
• BRD4 0
• BTK 0
• CDK4/6 0
• FAK 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

  NCT02962661· M.D. Anderson Cancer Center· Updated 2 Nov 2026

  “PI Request”Registry text, quoted unchanged. Source

• Terminated

  Tolerability and Safety of CARDIOMEMS™ Intracardiac Continuous Cardiac Hemodynamic Monitoring Device in Patients With Cardio Renal Syndrome With Severe Renal Impairment

  NCT05428631· Centre Hospitalier Universitaire de Nīmes· Updated 22 Oct 2026

  “Recruitment Challenges”Registry text, quoted unchanged. Source

• Terminated

  Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Heart Disease

  NCT05147766· The Foundation for Orthopaedics and Regenerative Medicine· Updated 20 Oct 2026

  “Inadequate treatment response observed in preliminary data did not justify enrolling further study participants”Registry text, quoted unchanged. Source

• Terminated

  BATwire Implant Kit Study

  NCT04600791· CVRx, Inc.· Updated 1 Oct 2026

  “Slow enrollment”Registry text, quoted unchanged. Source

• Withdrawn

  Evaluation of the Effectiveness of the CardioStory Device in Distinguishing Heart Failure From Other Causes in Patients Presenting With Dyspnea

  NCT07147699· Hôpital Universitaire Sahloul· Updated 30 Sept 2026

  “This record was withdrawn prior to enrollment. The study was subsequently re-registered under the sponsor's Responsible Party as NCT07685106, which reflects the transfer of study conduct from the investigator-initiated phase to the sponsoring compan”Registry text, quoted unchanged. Source

• Withdrawn

  Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure

  NCT06995144· Sarfez Pharmaceuticals, Inc.· Updated 28 Sept 2026

  “No participants enrolled”Registry text, quoted unchanged. Source

• Terminated

  Medico-economic Evaluation of Therapeutic Adaptation Guided by the Soluble Suppression of Tumorigenicity 2 (sST-2) Biomarker in the Management of Patients With Acute Heart Failure

  NCT04554277· University Hospital, Montpellier· Updated 24 Sept 2026

  “The inclusions were halted due to problems with the supply of the kits required for sST2 assays”Registry text, quoted unchanged. Source

• Terminated

  Transitions of Care Clinic (TOCC)

  NCT06937827· Hackensack Meridian Health· Updated 21 Sept 2026

  “Funding restrains”Registry text, quoted unchanged. Source

• Terminated

  Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)

  NCT04502316· CVRx, Inc.· Updated 17 Sept 2026

  “Participant follow-up through 12 months post-Barostim Implant sufficient for data collection and analysis purposes.”Registry text, quoted unchanged. Source

• Terminated

  External Body Pressure in Heart Failure With Preserved Ejection Fraction

  NCT05764564· Duke University· Updated 11 Sept 2026

  “Study was terminated at the completion of Aim 1 due to lack of time and funding to complete the more complex Aim 2.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• The CARDIOPROTECT Trial

  NCT07654426· Beth Israel Deaconess Medical Center· Source

• A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti

  NCT03892265· Washington University School of Medicine· Source

• A Study of Bimagrumab in Participants With HFpEF

  NCT07920887· Eli Lilly and Company· Source

• CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes

  NCT04709900· Copenhagen University Hospital, Rigshospitalet· Source

• WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department

  NCT07558265· Ohio State University· Source

• Rehabilitation Program for People With Methamphetamine-Associated Cardiopulmonary Conditions

  NCT07915882· Michael Incze· Source

• The Effect of Semi Fowler 30' Right Lateral on Cardiac Output in Acute Heart Failure

  NCT06039397· Universitas Indonesia· Source

• Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms (DECISION)

  NCT07113223· Idoven 1903 S.L.· Source

• Evaluating a Digital Aid to Improve ICD Decisions

  NCT07913204· Stanford University· Source

• Achieving Optimal Medical Therapy Through Percutaneous Treatment of Secondary Mitral Regurgitation to Improve Outcome in Patients With HFrEF

  NCT07758023· University Medical Center Mainz· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 17
• Organoids 5
• Mendelian Randomization Analysis 78
• CRISPR-Cas Systems 7
• Gene Expression Profiling 70
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 10
• Proteomics 106
• Metabolomics 63
• Mass Spectrometry 5
• Flow Cytometry 10
• Immunohistochemistry 13
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 37
• Magnetic Resonance Imaging 154
• Machine Learning 194
• Deep Learning 40
• Cohort Studies 495
• Genome-Wide Association Study 74

• Analysis of mRNA and microRNA profiles in ischemic cardiomyopathy with LVAD support.

  Mol Biol Rep, Oct 2026

• Multi-omic profiling of cardiomyocyte ageing and functional decline.

  Cardiovasc Res, Oct 2026

• Immune and inflammatory features associated with pyroptosis- and myocardial fibrosis-related genes in HFpEF: a machine learning study.

  Front Immunol, Oct 2026

• Multi-omics profiling reveals coordinated metabolic and immuno-inflammatory remodeling in a high-fat diet and single-dose streptozotocin-induced mouse model of diabetic cardiomyopathy.

  BMC Cardiovasc Disord, Sept 2026

• Integrated epigenomic and transcriptomic analyses implicate Car5b in cardiomyocyte hypertrophy.

  Biochem Biophys Res Commun, Sept 2026

• Cardiac proteomic and phosphoproteomic profiling defines clinically relevant molecular subgroups in human heart failure.

  Nat Cardiovasc Res, Sept 2026

• Integrated analysis of bulk transcriptomics and single-cell transcriptomics revealed the association characteristics between heart failure and β-hydroxybutyrylation-related genes.

  PLoS One, Sept 2026

• HMOX2-driven crosstalk between vascular aging and heart failure: A multimodal bioinformatics and explainable machine learning approach with experimental validation.

  PLoS One, Sept 2026

• Impaired antigen clearance of macrophages associates with heart failure and non-obstructive azoospermia: insights from transcriptomics, in silico knockout, and in vitro validation.

  Front Immunol, Sept 2026

• Network Pharmacology, GEO Transcriptomics, and Molecular Docking of Zhenwu Decoction with Wuling Powder for Chronic Heart Failure.

  J Vis Exp, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.